Table 1. Demographic profiles and... | American Society of Hematology

Table 1.

Demographic profiles and azathioprine characteristics for all 92 patients with ITP who received azathioprine

Demographic profiles	n (%)
Sex
Male	39 (42.4%)
Female	53 (57.6%)
Age at diagnosis, mean (± SD), y	55.6 (± 22.3)
Diagnosis
Primary ITP	64 (69.6%)
Secondary ITP∗	28 (30.4%)
Baseline platelet count, median (range), × 10⁹/L	22 (4-217)
Duration of ITP before starting azathioprine, median (range), wk	71 (1-2499)
Duration of follow-up, median (range), wk	338 (7-2801)
Azathioprine characteristics
Starting dose, median (range), mg/d	100 (25-150)
Maintenance dose, median (range)†, mg/d	100 (25-150)
Duration of treatment, median (range), wk	20 (1-1787)
Concurrent therapies
Corticosteroids	38 (41.3%)
Other immunosuppressive drugs	11 (12.0%)
TPO-RA	7 (7.6%)

Demographic profiles	n (%)
Sex
Male	39 (42.4%)
Female	53 (57.6%)
Age at diagnosis, mean (± SD), y	55.6 (± 22.3)
Diagnosis
Primary ITP	64 (69.6%)
Secondary ITP∗	28 (30.4%)
Baseline platelet count, median (range), × 10⁹/L	22 (4-217)
Duration of ITP before starting azathioprine, median (range), wk	71 (1-2499)
Duration of follow-up, median (range), wk	338 (7-2801)
Azathioprine characteristics
Starting dose, median (range), mg/d	100 (25-150)
Maintenance dose, median (range)†, mg/d	100 (25-150)
Duration of treatment, median (range), wk	20 (1-1787)
Concurrent therapies
Corticosteroids	38 (41.3%)
Other immunosuppressive drugs	11 (12.0%)
TPO-RA	7 (7.6%)

SD, standard deviation.

Defined as all forms of ITP except primary ITP; most patients had concomitant autoimmune diseases.

Defined as the dose at which patients were maintained on the longest to maintain the desired therapeutic effect.